University of Texas MD Anderson Cancer Center

Houston, Texas
Visiting Scientist, Department of Pediatrics
Chief Executive Officer, ZIOPHARM Oncology

Research

T-cells are part of the body’s immune system that is responsible for identifying, attacking and destroying diseased cells. However, cancer cells can hide. And in order for T-cells to get rid of cancer, they first have to “see” the cancer. Dr. Cooper and his team of researchers found a way to modify the T-cells collected from a leukemia or lymphoma patient and enable them to “see” the tumor cells.

The research team employed a genetic engineering technique that makes the T-cells carry a “cellular antenna” (chimeric antigen receptor or CAR), which specifically detects a molecule called CD19 that is found on the tumor cell surface of several types of leukemia and lymphoma (including Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Lymphomas of the B-lineage). When the CAR-T cells are fully-equipped and infused back to the same patient, they can mount full-blown immune attacks on tumor cells.

In addition, since cancerous tissues often contain less oxygenated cells, Dr. Cooper is developing an approach to make the engineered CAR-T cells seek out cancer cells specifically in tissues that are less oxygenated. Preliminary laboratory results are very encouraging.

Moving research to patient care, Dr. Cooper’s team recently published their laboratory results from a high throughput device that rapidly makes large numbers of CAR-T cells. Although it is still early in its development, Dr. Cooper predicts the innovative device will provide a faster and safer method for redirecting immune cells. Early in 2015, a new company, ZIOPHARM Oncology, was launched to translate Dr. Cooper’s adoptive immunotherapy approach into new treatments for patients in clinics across the U.S.

Bio

Laurence J.N. Cooper, M.D, Ph.D., is a visiting scientist at the University of Texas M.D. Anderson Cancer Center and CEO of ZIOPHARM Oncology. He graduated from Kenyon College in 1986 and received his M.D. and Ph.D. from Case Western Reserve University. He then completed his medical residency at the University of Washington Children’s Hospital and Regional Medical Center. Dr. Cooper finished his schooling with a fellowship at Fred Hutchinson Cancer Research Center.

Dr. Cooper joined the University of Texas MD Anderson Cancer Center in 2006, where his appointments included Tenured Professor in pediatrics and immunology, Section Chief of cell therapy at the Children’s Cancer Hospital and Associate Director at the Center for Cancer Immunology Research.

Dr. Cooper has received numerous awards and honors, including the 1994 Henry F. Sanders’ Award in Pediatrics from Case Western Reserve University, the 1999 Young Investigator Award from the American Society of Clinical Oncology, the 2004 American Society of Gene Therapy Young Investigator Award, the 2010 Best Boss Award at MD Anderson Cancer Center and the 2012 Robert M. Chamberlain Distinguished Mentor Award from MD Anderson Cancer Center.

He has also authored more than 140 journal articles, book chapters and abstracts, and is a member of many societies and organizations, including the American Society for Blood and Marrow Transplantation, the American Society of Gene and Cell Therapy, the American Society of Hematology, the California Medical Association, the Center for International Blood and Marrow Transplant, the Harris County Medical Society, the International Society for Biological Therapy of Cancer, the International Society for Cellular Therapy, the Lymphoma Research Foundation, the Follicular Lymphoma Consortium, the National Cancer Institute’s Pediatric Oncology Branch and the American Society for Clinical Investigation.

Laurence J.N. Cooper, M.D., Ph.D.

Area of Focus

Cancer Type

Years of NFCR Funding

2004 – 2015

Related Content

New Drug Makes Unresectable or Metastatic Ocular Cancer Treatable

New Research Sets Physical Activity Goals for Cancer Prevention

Getting the body moving can be particularly challenging during winter when many parts of the country are under an icy blanket of snow. Undoubtedly it is more comfortable to stay snuggled up on the couch dreaming of spring. However, new research shows that physical activity prevents cancer – and the gold standard is not as unattainable as one might think.  Exercise and Cancer Prevention This 2021 study published in Medicine & Science in Sports & Exercise reviewed the Behavioral Risk Factor Surveillance System results. This system collects self-reported data from individuals 30 years or older collected in all 50 states and Washington D.C. between 2013 and 2016. The study reveals that participating in five or more hours of exercise each week reduced the risk of seven different cancers. The seven cancers linked to physical inactivity include: 17% of stomach cancer cases  12% of endometrial cancer cases  11% of kidney cancer cases  9% of colon cancer cases 8% of esophageal cancer cases 7% of breast cancer cases in women, and  4% of urinary bladder cancers  Simply put, the team discovered that over 46,000 cases of cancer could potentially be avoided per year in the United States if the population met the recommended five hours/week of physical activity. What Kind of Physical Activity Should You Try?  While undertaking any type of physical activity may significantly reduce cancer risk, some types of exercise may be even more effective. A University of Sydney research team assembled to determine which form of exercise is the most effective at preventing cancer. After studying 80,000 adults, the team concluded that strength training is more effective at prolonging life than cardio workouts. The study considered multiple health variables, such as age, health status, and lifestyle. Even when accounting for these factors, the study found that strength training twice a week reduced the likelihood of dying from cancer by 31%. Actually, the overall probability of any kind of premature death decreased by 23%.  Exercise and Immunotherapy Response  Similarly, a 2021 study led by National Foundation for Cancer Research (NFCR)-funded scientist Dr. Rakesh Jain found that exercise training may slow tumor growth and improve outcomes for females with breast cancer – especially those treated with immunotherapy drugs. The team used animal models of breast cancer in this study, which showed physical activity increasing levels of cancer-fighting immune cells. Tumors in mouse models of human breast cancer grew more slowly in mice put through their paces in a structured aerobic exercise program than in sedentary mice. The tumors in exercised mice exhibited an increased anti-tumor immune response. Additionally, the tumors grew more slowly in mice that performed exercise training. Living a Cancer-Preventative Lifestyle Regular exercise can significantly improve one’s overall health concerning cancer, other serious diseases, mental health, and general wellbeing. Many researchers continue to explore how best to reap the benefits of a well-balanced lifestyle, and NFCR is committed to providing free evidence-based guidance in its monthly Cancer-Fighting Lifestyle blog and YouTube Channel.  Additional Reads You May Enjoy: Mushrooms for Cancer Prevention and Mental Wellbeing Genetic Predisposition vs. Healthy Living: Which Impacts Cancer Risk More? 5 Ways Spending More Time Outside Benefits Our Health Stay connected with us! Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer […]

New Treatment with Combined Immunotherapies is Effective for Drug Resistant Metastatic Lung Cancer